# A Study of 177Lu-PSMA-617 in People With Gliomas

> **NCT07223034** · PHASE1 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 20 (estimated)

## Conditions studied

- Glioma
- Diffuse Astrocytoma, IDH-Wildtype (Grade 2-4)
- Glioblastoma, IDH-wildtype
- Diffuse Midline Glioma, H3 K27-Altered
- Diffuse Hemispheric Glioma, H3 G34-mutant
- Diffuse Pediatric-type High-grade Glioma, H3-wildtype and IDH-wildtype

## Interventions

- **DRUG:** Temozolomide
- **DRUG:** 177Lu-PSMA-617
- **DIAGNOSTIC_TEST:** 68Ga-PSMA-PET scan/ MRI
- **BEHAVIORAL:** Quality of Life Questionnaires

## Key facts

- **NCT ID:** NCT07223034
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-27
- **Primary completion:** 2027-10
- **Final completion:** 2027-10
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-11-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07223034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07223034, "A Study of 177Lu-PSMA-617 in People With Gliomas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07223034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*